ImmunoGenesis, Inc.

01/09/2023

Our CEO, Jim Barlow, is onsite during JPM week in San Francisco. Connect to learn more about ImmunoGenesis and our novel approach to treating cold, immune-excluded tumors.

We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.

11/14/2022

Our lead program, IMGS-001, was presented last week at . Take a look at our posters to find out why we’re so enthusiastic about the future of cancer care.

We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.

11/03/2022

We’re thrilled to be presenting 2 posters on our lead development program, IMGS-001, at . If you’ll be attending, stop by and find out how we’re advancing cancer care. After the conference, we’ll be sharing both posters on immunogenesis.com.

Find more details in our press release.

https://www.immunogenesis.com/immunogenesis-to-present-pre-clinical-data-from-lead-program-at-society-for-immunotherapy-of-cancer-conference/

We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.

06/03/2022

We are excited to take the next step in advancing cancer care through our partnership with Agenus Inc. This partnership advances our vision to bring promising immunotherapies to patients who have “cold” tumors. Patients are waiting.

We invite you to read the press release announcing our collaboration.

LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that it has entered into 3 new clinical collaborations with

02/09/2022

We are pleased to announce that our CEO, James Barlow is presenting at BIO CEO & Investor Conference about our therapeutic development programs targeting “cold” tumors.

We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.

01/21/2022

Get to know the people behind the ideas. Watch our team members express the compassion and enthusiasm that drive ImmunoGenesis.

01/04/2022

We are excited to announce that our CEO, James Barlow, is presenting our clinical development program targeting “cold” cancers at Biotech Showcase on January 10.

We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.

12/14/2021

Joining our powerhouse team is industry veteran Charles Schweizer, PhD, as Senior VP of Clinical Development.

We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.

11/16/2021

We were honored to present 6 posters on our lead program at the Society for Immunotherapy of Cancer 2021 meeting.

We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.

11/03/2021

We are thrilled to announce that we’ll be presenting 6 posters on our lead program at the Society for Immunotherapy of Cancer 2021 meeting.

We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.

08/31/2021

Exciting new publications with positive data for our STING agonist. Explore the potential applications in immunologically resistant cancers.

We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.